Patents by Inventor Stephen Wright

Stephen Wright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240033229
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD appears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.
    Type: Application
    Filed: February 16, 2023
    Publication date: February 1, 2024
    Inventors: Geoffrey GUY, Stephen WRIGHT, Alice MEAD, Anne COMI
  • Patent number: 11865126
    Abstract: The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.
    Type: Grant
    Filed: June 15, 2023
    Date of Patent: January 9, 2024
    Assignee: Compass Pathfinder Limited
    Inventors: Derek John Londesbrough, Christopher Brown, Julian Scott Northen, Gillian Moore, Hemant Kashinath Patil, David E. Nichols, Megan Croal, Hans Åke Eriksson, George Goldsmith, Molly Tabitha Hickey, Shaun Hurley, Ekaterina Malievskaia, Lindsey Marwood, Drummond E-Wen Joe Mcculloch, Laurie Emma Medhurst, Nathan Poulsen, Aslihan Selimbeyoglu, Anaïs Soula, Amanda Tan Shuxiang, Manon Cecile Elisabeth Veraart, Tobias Patrick Whelan, Lars Christian Wilde, Stephen Wright
  • Patent number: 11857913
    Abstract: Provided are apparatus and systems for performing a swing adsorption process. This swing adsorption process may involve performing dampening for fluctuations in the streams conducted away from the adsorbent bed unit. The process may be utilized for swing adsorption processes, such as rapid cycle TSA and/or rapid cycle PSA, which are utilized to remove one or more contaminants from a gaseous feed stream.
    Type: Grant
    Filed: March 29, 2022
    Date of Patent: January 2, 2024
    Assignee: ExxonMobil Technology and Engineering Company
    Inventors: Ananda K. Nagavarapu, Stephen Wright, Bennett D. Marshall, Brett L. Ryberg
  • Publication number: 20230330117
    Abstract: The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.
    Type: Application
    Filed: June 15, 2023
    Publication date: October 19, 2023
    Applicant: Compass Pathfinder Limited
    Inventors: Derek John LONDESBROUGH, Christopher BROWN, Julian Scott NORTHEN, Gillian MOORE, Hemant Kashinath PATIL, David E. NICHOLS, Megan CROAL, Hans Åke ERIKSSON, George GOLDSMITH, Molly Tabitha HICKEY, Shaun HURLEY, Ekaterina MALIEVSKAIA, Lindsey MARWOOD, Drummond E-Wen Joe MCCULLOCH, Laurie Emma MEDHURST, Nathan POULSEN, Aslihan SELIMBEYOGLU, Anaïs SOULA, Amanda Tan SHUXIANG, Manon Cecile Elisabeth VERAART, Tobias Patrick WHELAN, Lars Christian WILDE, Stephen WRIGHT
  • Patent number: 11774315
    Abstract: A flexible lid seal detector incorporates a compression body having a cavity including a sensor. The detector has a distal end comprising a plurality of concentric compression rings surrounding the cavity. An outer-most ring is defined by outer and inner shaping rims. The distal end includes a recessed lid deflection volume defined by the inner rim and a distal surface of the compression body. The deflection volume may receive a portion of a flexible lid when at least one of the rings applies a compressive force thereto, thereby deforming the lid into the deflection volume. The deflection volume may include a second compression ring and its respective inner and outer shaping rims. A seal detector system may include the detector with a controller configured to receive data from the sensor for a predetermined period of time while the detector applies the compressive force to the lid.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: October 3, 2023
    Assignee: TELEDYNE INSTRUMENTS, INC.
    Inventors: Eric E. Meade, Stephen Wright
  • Publication number: 20230301936
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: May 19, 2023
    Publication date: September 28, 2023
    Inventors: Geoffrey GUY, Stephen WRIGHT, Orrin DEVINSKY
  • Patent number: 11766411
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: September 26, 2023
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 11752111
    Abstract: The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a further embodiment the invention relates to the use of CBDV in the treatment of schizophrenia. CBDV has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS, AS and schizophrenia. The CBDV is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDV is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDV is synthetically produced.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: September 12, 2023
    Assignee: GW RESEARCH LIMITED
    Inventors: Geoffrey Guy, Stephen Wright, James Brodie, Marie Woolley-Roberts, Rafael Maldonado, Daniela Parolaro, Livio Luongo, Joanna Neill
  • Patent number: 11738035
    Abstract: The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.
    Type: Grant
    Filed: December 8, 2022
    Date of Patent: August 29, 2023
    Assignee: Compass Pathfinder Limited
    Inventors: Derek John Londesbrough, Christopher Brown, Julian Scott Northen, Gillian Moore, Hemant Kashinath Patil, David E. Nichols, Megan Croal, Hans Åke Eriksson, George Goldsmith, Molly Tabitha Hickey, Shaun Hurley, Ekaterina Malievskaia, Lindsey Marwood, Drummond E-Wen Joe McCulloch, Laurie Emma Medhurst, Nathan Poulsen, Aslihan Selimbeyoglu, Anaïs Soula, Amanda Tan Shuxiang, Manon Cecile Elisabeth Veraart, Tobias Patrick Whelan, Lars Christian Wilde, Stephen Wright
  • Publication number: 20230263744
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of Angelman syndrome (AS). CBD has been shown to be particularly effective in improving anxiety in rodent models of AS. The CBD is preferably substantially pure. It may take the form of a highly purified extract of Cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBD is synthetically produced. Alternatively, the CBD may be used as a botanical drug substance (BDS) from a Cannabis plant in which CBD is the predominant cannabinoid. The CBD may also be present in combination with other cannabinoids and non-cannabinoid components such as terpenes. In use the CBD may be used concomitantly with one or more other medicaments. Alternatively, the CBD may be formulated for administration separately, sequentially or simultaneously with one or more medicaments or the combination may be provided in a single dosage form.
    Type: Application
    Filed: May 2, 2023
    Publication date: August 24, 2023
    Inventors: Geoffrey Guy, Stephen Wright, James Brodie, Marie Woolley-Roberts, Livio Luongo
  • Publication number: 20230248664
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: March 20, 2023
    Publication date: August 10, 2023
    Inventors: Geoffrey GUY, Stephen WRIGHT, Orrin DEVINSKY
  • Patent number: 11701330
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: July 18, 2023
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 11679087
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of Angelman syndrome (AS). CBD has been shown to be particularly effective in improving anxiety in rodent models of AS. The CBD is preferably substantially pure. It may take the form of a highly purified extract of Cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBD is synthetically produced. Alternatively, the CBD may be used as a botanical drug substance (BDS) from a Cannabis plant in which CBD is the predominant cannabinoid. The CBD may also be present in combination with other cannabinoids and non-cannabinoid components such as terpenes. In use the CBD may be used concomitantly with one or more other medicaments. Alternatively, the CBD may be formulated for administration separately, sequentially or simultaneously with one or more medicaments or the combination may be provided in a single dosage form.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: June 20, 2023
    Inventors: Geoffrey Guy, Stephen Wright, James Brodie, Marie Woolley-Roberts, Livio Luongo
  • Patent number: 11633369
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: April 25, 2023
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Publication number: 20230124137
    Abstract: The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.
    Type: Application
    Filed: December 8, 2022
    Publication date: April 20, 2023
    Applicant: COMPASS PATHFINDER LIMITED
    Inventors: Derek John LONDESBROUGH, Christopher BROWN, Julian Scott NORTHEN, Gillian MOORE, Hemant Kashinath PATIL, David E. NICHOLS, Megan CROAL, Hans Åke ERIKSSON, George GOLDSMITH, Molly Tabitha HICKEY, Shaun HURLEY, Ekaterina MALIEVSKAIA, Lindsey MARWOOD, Drummond E-Wen Joe MCCULLOCH, Laurie Emma MEDHURST, Nathan POULSEN, Aslihan SELIMBEYOGLU, Anaïs SOULA, Amanda Tan SHUXIANG, Manon Cecile Elisabeth VERAART, Tobias Patrick WHELAN, Lars Christian WILDE, Stephen WRIGHT
  • Publication number: 20230032502
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of of nocturnal snoring. In particular the CBD appears particularly effective in treating nocturnal snoring in children and young adults with epilepsy The disclosure further relates to the use of CBD in 5 combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: March 28, 2022
    Publication date: February 2, 2023
    Inventors: Geoffrey GUY, Stephen WRIGHT, Alice MEAD, Orrin DEVINSKY
  • Patent number: 11564935
    Abstract: The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.
    Type: Grant
    Filed: December 2, 2021
    Date of Patent: January 31, 2023
    Assignee: COMPASS Pathfinder Limited
    Inventors: Derek John Londesbrough, Christopher Brown, Julian Scott Northen, Gillian Moore, Hemant Kashinath Patil, David E. Nichols, Megan Croal, Hans Åke Eriksson, George Goldsmith, Molly Tabitha Hickey, Shaun Hurley, Ekaterina Malievskaia, Lindsey Marwood, Drummond E-Wen Joe McCulloch, Laurie Emma Medhurst, Nathan Poulsen, Aslihan Selimbeyoglu, Anaïs Soula, Amanda Tan Shuxiang, Manon Cecile Elisabeth Veraart, Tobias Patrick Whelan, Lars Christian Wilde, Stephen Wright
  • Publication number: 20230023092
    Abstract: The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat depression, neurocognitive disorders, autism spectrum disorder, and/or attention-deficit/hyperactivity disorder.
    Type: Application
    Filed: April 17, 2020
    Publication date: January 26, 2023
    Inventors: Derek John LONDESBROUGH, Christopher BROWN, Julian Scott NORTHEN, Gillian MOORE, Hemant Kashinath PATIL, David E. NICHOLS, Megan CROAL, Hans Ake ERIKSSON, George GOLDSMITH, Molly Tabitha HICKEY, Shaun HURLEY, Ekaterina MALIEVSKAIA, Lindsey MARWOOD, Drummond E-Wen Joe MCCULLOCH, Laurie Emma MEDHURST, Nathan POULSEN, Aslihan SELIMBEYOGLU, Anais SOULA, Amanda Tan SHUXIANG, Manon Cecile Elisabeth VERAART, Tobias Patrick WHELAN, Lars Christian WILDE, Stephen WRIGHT
  • Publication number: 20230000883
    Abstract: The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.
    Type: Application
    Filed: April 17, 2020
    Publication date: January 5, 2023
    Inventors: Derek John LONDESBROUGH, Christopher BROWN, Julian Scott NORTHEN, Gillian MOORE, Hemant Kashinath PATIL, David E. NICHOLS, Megan CROAL, Hans Ake ERIKSSON, George GOLDSMITH, Molly Tabitha HICKEY, Shaun HURLEY, Ekaterina MALIEVSKAIA, Lindsey MARWOOD, Drummond E-Wen Joe MCCULLOCH, Laurie Emma MEDHURST, Nathan POULSEN, Aslihan SELIMBEYOGLU, Anais SOULA, Amanda Tan SHUXIANG, Manon Cecile Elisabeth VERAART, Tobias Patrick WHELAN, Lars Christian WILDE, Stephen WRIGHT
  • Publication number: 20220395471
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: August 11, 2022
    Publication date: December 15, 2022
    Inventors: Geoffrey GUY, Stephen Wright, Orrin Devinsky